NCT04321616

The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients

The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 700 (estimated)
• Sponsor: Oslo University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19. This trial will follow the core WHO protocol but has additional efficacy, safety and explorative endpoints.

Conditions

• SARS-CoV Infection
• COVID 19
• Acute Respiratory Distress Syndrome ARDS

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
DRUG	Remdesivir	Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
OTHER	(Standard of Care) SoC	The standard of care will be supplied to all patients not receiving a drug intervention.

Timeline

• Start date: 2020-03-28
• Primary completion: 2020-08-01
• Completion: 2020-11-01
• First posted: 2020-03-25
• Last updated: 2020-04-14

Locations

1 site across 1 country: Norway